Zong R T, Scheuermann R H
Laboratory of Molecular Pathology, University of Texas Southwestern Medical Center, Dallas 75235-9072, USA.
J Biol Chem. 1995 Oct 13;270(41):24010-8. doi: 10.1074/jbc.270.41.24010.
The immunoglobulin heavy chain (IgH) intronic enhancer stimulates transcription from functional promoters in B lymphocytes but not other cell types. The observation that binding sites for the nuclear factor-mu negative regulator (NF-muNR) enhancer repressor overlap nuclear matrix attachment regions (MARs) in this enhancer has lead to the hypothesis that the cell type specificity of the enhancer might be controlled by regulating nuclear matrix attachment (Scheuermann, R. H., and Chen, U. (1989) Genes & Dev. 3, 1255-1266). To understand the role of MARs in IgH enhancer regulation, we have identified a novel MAR-binding protein, MAR-BP1, from soluble nuclear matrix preparations based on its ability to bind to the MARs associated with the IgH enhancer. Purified MAR-BP1 migrates as a 33-kDa protein, and it can be found in nuclear matrix preparations from a number of different types of lymphoid cell lines. Although specific binding sites have been difficult to localize by chemical or enzymatic footprinting procedures, NF-muNR binding sites are critical for efficient MAR-BP1 binding. Indeed, binding of the IgH enhancer to either intact nuclear matrix preparations or to MAR-BP1 is mutually exclusive to NF-muNR binding. These results are consistent with a model for cell-type specific regulation in which binding of the NF-muNR repressor to the IgH enhancer prevents nuclear matrix attachment in inappropriate cells by interfering with MAR-BP1/enhancer interaction.
免疫球蛋白重链(IgH)内含子增强子可刺激B淋巴细胞中功能性启动子的转录,但对其他细胞类型则无此作用。核因子-μ负调节因子(NF-μNR)增强子阻遏物的结合位点与该增强子中的核基质附着区域(MARs)重叠,这一观察结果引出了一个假说,即增强子的细胞类型特异性可能通过调节核基质附着来控制(Scheuermann, R. H., and Chen, U. (1989) Genes & Dev. 3, 1255 - 1266)。为了了解MARs在IgH增强子调控中的作用,我们基于其与IgH增强子相关的MARs结合能力,从可溶性核基质制剂中鉴定出一种新型的MAR结合蛋白MAR-BP1。纯化后的MAR-BP1以33 kDa蛋白形式迁移,并且可以在多种不同类型的淋巴细胞系的核基质制剂中找到。尽管通过化学或酶足迹法难以定位特定的结合位点,但NF-μNR结合位点对于有效的MAR-BP1结合至关重要。实际上,IgH增强子与完整核基质制剂或与MAR-BP1的结合与NF-μNR结合相互排斥。这些结果与一种细胞类型特异性调控模型一致,即NF-μNR阻遏物与IgH增强子的结合通过干扰MAR-BP1/增强子相互作用,阻止了不适当细胞中的核基质附着。